News Incyte’s oral vitiligo drug heading for phase 3 Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in pati
News FDA finally okays Novavax's COVID-19 jab, with restrictions The FDA has granted full approval to Novavax's COVID-19 vaccine after a delay, but has limited its use.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.